U.S., March 28 -- ClinicalTrials.gov registry received information related to the study (NCT07498335) titled 'Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary IgAN' on March 23.
Brief Summary: A Phase III, single-arm, multicenter pediatric clinical study evaluating atrasentan in children and adolescents aged 2 to <18 years with primary immunoglobulin A nephropathy (IgAN).
Study Start Date: Oct. 02, 2026
Study Type: INTERVENTIONAL
Condition:
Berger Disease
Bergers Disease
IgA Nephropathy
Immunoglobulin A Nephropathy
Primary IgAN
Nephritis IgA Type, Nephropathy IgA Type
Intervention:
DRUG: Drug: Atrasentan
* 104 Weeks - Film-coated tablet
* Other Names:
Atrasent...